Literature DB >> 321713

Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis.

L J Strausbaugh, C D Mandaleris, M A Sande.   

Abstract

Tobramycin, sisomicin, and amikacin were compared with gentamicin in the therapy of experimental E. coli meningitis in rabbits. Meningitis was produced in 40 animals by intracisternal injection of 10(5) E. coli. Three dosages of each antibiotic were administered intravenously over 8 hours. Serum and CSF samples were obtained at 0,2,4,6, and 8 hours for determination of aminoglycoside concentrations and CSF bacteria counts. The four aminoglycosides demonstrated comparable penetration into the CSF. The mean percent penetration (CSF conc./serum conc. X 100%) with the three dosages was 10 to 50% for gentamicin, 8 to 23% for tobramycin, 6 to 16% for sisomicin, and 11 to 23% for amikacin. This variation in penetration reflected individual differences in each dosage group and the increase in percent penetration that was observed during therapy. Sisomicin and gentamicin were consistently bactericidal in vivo. Mean CSF bacterial titers gentamicin were consistently bactericidal in vivo. Mean CSF bacterial titers decreased 3.07 logs in rabbits treated with sisomicin and 2.44 logs in animals treated with gentamicin. Even through CSF concentrations were comparable, the group treated with tobramycin demonstrated only a 0.64 log decrease and the amikacin group had a 0.45 log increase in mean CSF titers. The bactericidal effect of sisomicin appeared to be more rapid than that of gentamicin. During the first 2 hours of therapy CSF titers declined 1.02 logs in animals treated with sisomicin as compared to 0.37 log in animals receiving gentamicin even though gentamicin concentrations were higher (mean 7.4 vs. 4.1 gm./ml.). Sisomicin also demonstrated greater bactericidal activity than the other aminoglycosides in normal CSF in vitro. The results of this study suggest that sisomicin may be of value in the therapy of E. coli meningitis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 321713

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  16 in total

1.  Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates.

Authors:  K Allegaert; I Scheers; E Adams; G Brajanoski; V Cossey; B J Anderson
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

2.  Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.

Authors:  W Kern; S L Kennedy; M Sachdeva; E R Sande; D Gunderson; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges.

Authors:  J S Bakken; J N Bruun; P Gaustad; T C Tasker
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

Review 5.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 6.  Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

Authors:  P Noone
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

7.  Comparison of netilmicin with gentamicin in the therapy of experimental Escherichia coli meningitis.

Authors:  W M Scheld; R S Brown; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.

Authors:  W M Scheld; M A Sande
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

9.  Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis.

Authors:  J L Gaillard; C Silly; A Le Masne; B Mahut; F Lacaille; G Cheron; V Abadie; P Hubert; V Matha; C Coustere
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 10.  Bacterial meningitis. Rational selection and use of antibacterial drugs.

Authors:  M Whitby; R Finch
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.